Page 13 - OB Risks - Delivering the Goods (Part Two)
P. 13

SVMIC Obstetrics Risks: Delivering the Goods




                        The patient met with the maternal fetal medicine
                        specialist on June 21st and an ultrasound at that time
                        showed a positive fetal pole, heart rate 175, and 9-week,

                        1-day gestational age. No abnormalities were seen. The

                        patient was counseled regarding methotrexate exposure
                        and the strong possibility of birth defects. The specialist
                        recommended anatomic survey at 18 weeks and noted

                        that the patient was uncertain about whether to continue

                        the pregnancy. On the same day, the patient also saw
                        her OB and it was documented that she was extremely
                        upset about the strong possibility of fetal abnormalities.

                        After a lengthy discussion with her OB, the patient stated

                        that she elected to terminate the pregnancy. Because
                        methotrexate does not have a definite guarantee of defects
                        in all pregnancies, the Ethics Committee at the hospital

                        would not approve termination locally and the patient

                        had to go out-of-state for the abortion on June 28th. A
                        lawsuit for malpractice was filed against the obstetrician.



                        Weak Points identified:

                          1.  The gestational sac seen in the uterus at the first

                              emergency room visits was essentially ignored.

                          2. There was no repeat ultrasound as recommended

                              prior to administering methotrexate.


                          3. The diagnosis of ectopic pregnancy was made after
                              laparoscopy clearly did not confirm same.


                          4.  Administering the methotrexate put the fetus at high
                              risk of fetal abnormalities and the patient’s decision

                              to abort followed.






                                                           Page 13
   8   9   10   11   12   13   14   15   16   17   18